LPX- TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin (Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid ...

Malaria, particularly in its severe forms, remains a global health and economic burden. It causes the deaths of more than 600 ...

The results of central nervous regulation in mice provide a new neural circuit and receptor regulatory mechanisms for the recovery of consciousness after midazolam administration.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

(9) A Phase I clinical trial is underway in Japan in patients with estrogen receptor-positive and HER2-negative breast cancer ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...

Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...